Cannabidiol as a Treatment for Social Anxiety Disorder (R61)
Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
The R61 will include two CBD dose levels vs placebo (PBO) and examine potential engagement
with two primary targets in a 3-week randomized controlled trial design. Willing and eligible
subjects will be randomized to one of three randomized double-blind treatments (n = 20 each
group): 1) CBD 800 mg (400 mg twice daily), 2) CBD 400 mg (200 mg twice daily), or 3) PBO
twice daily for three weeks.
Participation is estimated at approximately 1 month from end of screening to endpoint for the
primary R61 study period. This includes screening, baseline, week 2 TSST, and Week 3 2-day
imaging paradigm, and clinical safety assessments at weeks 2 and 3.
Phase:
Phase 2
Details
Lead Sponsor:
NYU Langone Health
Collaborators:
Ananda Scientific National Center for Complementary and Integrative Health (NCCIH)